Total Sleep Duration and Risk of Type 2 Diabetes: Evidence-Based On Clinical and Epidemiological Studies
Methods: Adhering to the state of information available, studies recruited between 2010- 2016 a total of seven prospective studies including systematic review and meta-analysis were used to establish the relationship between sleep duration and type 2 diabetes. Studies were identified from Medline and Scopus. Studies included in this review was considered based on the different aspects such as maximum follow-up period, number of participants, including both sexes along with similar reference criteria of sleep duration.
Results: With U-shaped association between sleep duration and the onset of diabetes, both short and long-term sleep duration was found contributing to the development of type 2 diabetes. Additionally, studies on the sex-related difference and pervasiveness of diabetes have also reported a profound relationship between short and long sleep hours and risk of developing type 2 diabetes.
Conclusion: Our study supports other studies on the relationship between total sleep duration and the risk of developing type 2 diabetes. This review emphasizes the importance of total sleep duration, sleep quality as a risk marker in monitoring type 2 diabetes.
Document Type: Review Article
Publication date: October 1, 2018
This article was made available online on July 19, 2018 as a Fast Track article with title: "Total Sleep Duration and Risk of Type 2 Diabetes: Evidence-Based On Clinical and Epidemiological Studies".
- Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. The journal covers the following areas:
In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites and adducts.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites